Pediatrix Medical Group, Inc.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Pediatrix Medical Group, Inc. | |||
| Date: | February 19, 2026 | By: | /s/ Mark S. Ordan |
|---|---|---|---|
| Mark S. Ordan | |||
| Chief Executive Officer | |||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Mark S. Ordan | Chief Executive Officer and Director | February 19, 2026 |
| Mark S. Ordan | (Principal Executive Officer) | |
| /s/ Kasandra H. Rossi | Chief Financial Officer | February 19, 2026 |
| Kasandra H. Rossi | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Guy P. Sansone | Lead Independent Director | February 19, 2026 |
| Guy P. Sansone | ||
| /s/ Laura A. Linynsky | Director | February 19, 2026 |
| Laura A. Linynsky | ||
| /s/ Thomas A. McEachin | Director | February 19, 2026 |
| Thomas A. McEachin | ||
| /s/ Kurt D. Newman, M.D. | Director | February 19, 2026 |
| Kurt D. Newman, M.D. | ||
| /s/ Michael A. Rucker | Director | February 19, 2026 |
| Michael A. Rucker | ||
| /s/ John M. Starcher, Jr. | Director | February 19, 2026 |
| John M. Starcher, Jr. | ||
| /s/ Shirley A. Weis | Director | February 19, 2026 |
| Shirley A. Weis | ||
| /s/ Sylvia J. Young | Director | February 19, 2026 |
| Sylvia J. Young | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.